Is fat-free mass the same as muscle mass?

No. It includes bone, organs, connective tissue, body water and blood-forming tissue as well as skeletal muscle.

Why do early fat-free mass drops look so large?

Body water and glycogen move quickly, and glycogen is stored with water. Early changes are substantially fluid rather than tissue.

Does weight loss affect bone?

Yes. Bone responds to mechanical loading, and carrying less mass reduces it — a distinct process from muscle protein balance.

GLP-1 & Incretin Science

What Fat-Free Mass Actually Contains

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Fat-free mass is everything in the body that is not fat — skeletal muscle, but also bone, organs, connective tissue, body water and haematopoietic tissue. Reporting a change in fat-free mass as though it were a change in muscle misstates what was measured.

Key facts

Includes: Muscle, bone, organs, water, blood-forming tissue
Muscle share: Well under half in most adults
Largest confounder: Body water shifts
Bone is affected too: Stefanakis 2024 (PMID 39481534)
Common error: Reading fat-free mass as muscle mass
Measured by: DXA, bioimpedance — not directly observed

What the compartment contains

Body composition analysis divides mass into fat and everything else. That everything else includes skeletal muscle, the skeleton, all internal organs, connective tissue, extracellular and intracellular water, and blood together with the marrow producing it. Skeletal muscle is a substantial component and it is not the majority.

Why water dominates the short-term signal

Body water is a large fraction of fat-free mass and it moves quickly. Glycogen is stored with water, so depleting glycogen reduces measured fat-free mass without any tissue being lost. Early rapid drops in fat-free mass during weight loss are substantially water and glycogen, which is why the early numbers overstate what has happened structurally.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

The finding the title of Stefanakis makes explicit

Stefanakis and colleagues published on the impact of weight loss on fat-free mass, muscle, bone and haematopoiesis health in Metabolism in 2024. Listing those four separately is the point: bone and blood-forming tissue are affected by weight loss and are not muscle. A discussion that reduces the whole compartment to muscle has already lost most of what the paper is about.

Why bone matters independently

Bone density responds to mechanical loading, and carrying less mass means less loading. That is a distinct process from muscle protein balance, it operates on a slower timescale, and it has its own long-term consequences. It cannot be addressed by the same interventions that address muscle, which is why it deserves separate consideration rather than being folded into a lean mass discussion.

What this means for reading a percentage

A reported percentage of lean mass lost is a change in a heterogeneous compartment measured by an indirect method. It is not a muscle biopsy. Comparing such percentages between trials that used different methods, at different timepoints, in differently hydrated participants, is considerably less informative than the precision of the numbers implies.

The practical consequence

Compounds designed to preserve muscle address one component of the compartment. Even complete success against muscle loss would leave bone and water changes untouched, so a trial reporting preserved lean mass has not necessarily preserved everything the compartment contains.

Quick reference

Component	In fat-free mass?	Changes with weight loss
Skeletal muscle	Yes	Yes — the usual focus
Bone	Yes	Yes — via reduced loading
Body water and glycogen	Yes	Rapidly, early
Organs and connective tissue	Yes	Yes
Adipose tissue	No	The intended target

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is fat-free mass the same as muscle mass?: No. It includes bone, organs, connective tissue, body water and blood-forming tissue as well as skeletal muscle.
Why do early fat-free mass drops look so large?: Body water and glycogen move quickly, and glycogen is stored with water. Early changes are substantially fluid rather than tissue.
Does weight loss affect bone?: Yes. Bone responds to mechanical loading, and carrying less mass reduces it — a distinct process from muscle protein balance.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum